A Phase 3 interventional study of Sitagliptin and Comparator: Rosiglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 60th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2006, is one of 74 in phase 3, and was the 34th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 273 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 76th largest by enrollment of the 170 interventional ones that give a count, is one of 12 that started in 2006, is one of 86 in phase 3, and was the 33rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin 100 mg
Drug: Sitagliptin · Drug: Comparator: Metformin
rosiglitazone 8 mg
Drug: Comparator: Rosiglitazone · Drug: Comparator: Metformin
placebo
Drug: Comparator: Placebo · Drug: Comparator: Metformin
Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
Also known as: Januvia
Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
Also known as: Avandia
placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Hemoglobin A1C (A1C) at Week 18
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent. The study hypothesis comparison was between sitagliptin versus placebo.
Time frame: Baseline and 18 Weeks
Fasting Plasma Glucose (FPG) at Week 18
The change from baseline is the Week 18 FPG minus the Week 0 FPG.
Time frame: Baseline and 18 Weeks
2-hour Post-meal Glucose (PMG) at Week 18
The change from baseline is the Week 18 PMG minus the Week 0 PMG.
Time frame: Baseline and 18 Weeks
First Patient In: 16-June-2006. Last Patient Last Visit: 2-March-2007. 13 medical clinics in 3 countries in Europe and 23 in 4 countries in the rest of the world
| Milestone | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| Started | 94 | 87 | 92 |
| Completed | 85 | 85 | 84 |
| Not completed | 9 | 2 | 8 |
| Withdrew: Adverse event | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject and other | 5 | 0 | 2 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent. The study hypothesis comparison was between sitagliptin versus placebo.
| Percent of glycosylated hemoglobin (A1C) | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| Hemoglobin A1C (A1C) at Week 18 | -0.73 (-0.87 to -0.60) | -0.79 (-0.92 to -0.65) | -0.22 (-0.36 to -0.08) |
The change from baseline is the Week 18 FPG minus the Week 0 FPG.
| mg/dL | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| Fasting Plasma Glucose (FPG) at Week 18 | -11.7 (-18.6 to -4.9) | -24.5 (-31.6 to -17.5) | 6.1 (-0.8 to 13.1) |
The change from baseline is the Week 18 PMG minus the Week 0 PMG.
| mg/dL | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| 2-hour Post-meal Glucose (PMG) at Week 18 | -35.4 (-46.3 to -24.5) | -51.3 (-62.5 to -40.1) | -4.9 (-16.0 to 6.1) |
Collected over Weeks 0 to 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 5/94 (5.3%) | 5/94 (5.3%) |
| Rosiglitazone | — | 5/87 (5.7%) | 1/87 (1.1%) |
| Placebo | — | 5/91 (5.5%) | 0/91 (0%) |
| Event | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 2/94 | 3/87 | 2/91 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/94 | 1/87 | 0/91 |
| SyncopeNervous system disorders | 0/94 | 1/87 | 0/91 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/94 | 0/87 | 1/91 |
| Endometrial hyperplasiaReproductive system and breast disorders | 0/94 | 0/87 | 1/91 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/94 | 0/87 | 1/91 |
| Angina unstableCardiac disorders | 1/94 | 0/87 | 0/91 |
| Coronary artery diseaseCardiac disorders | 1/94 | 0/87 | 0/91 |
| Skin lacerationInjury, poisoning and procedural complications | 1/94 | 0/87 | 0/91 |
| Event | Sitagliptin | Rosiglitazone | Placebo |
|---|---|---|---|
| Blood glucose increasedInvestigations | 5/94 | 1/87 | 0/91 |
| Age, Continuous(years) | Sitagliptin | Rosiglitazone | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 9.8 | 54.8 ± 10.5 | 55.3 ± 9.3 | 55.1 ± 9.8 |
| Sex: Female, Male(Participants) | Sitagliptin | Rosiglitazone | Placebo | Total |
|---|---|---|---|---|
| Female | 42 | 32 | 38 | 112 |
| Male | 52 | 55 | 54 | 161 |
| Race/Ethnicity, Customized(participants) | Sitagliptin | Rosiglitazone | Placebo | Total |
|---|---|---|---|---|
| White | 57 | 51 | 56 | 164 |
| Black | 0 | 1 | 0 | 1 |
| Asian | 36 | 33 | 36 | 105 |
| Other | 1 | 2 | 0 | 3 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Sitagliptin | Rosiglitazone | Placebo | Total |
|---|---|---|---|---|
| Mean | 157.5 ± 31.4 | 156.9 ± 31.6 | 160.0 ± 37.4 | 158.1 ± 33.5 |
| Hemoglobin A1C (A1C)(Percent of glycosylated hemoglobin (A1C)) | Sitagliptin | Rosiglitazone | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.8 ± 1.0 | 7.7 ± 0.8 | 7.7 ± 0.9 | 7.7 ± 0.9 |
No study locations are listed for this record.
The record gives a start of Jun 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin